Skip to content
Homepage
Clinic directory

Clinics in Los Angeles, California

Every listing is checked against federal records, reviewed for evidence, and confirmed still operating. No pay-to-play. No guesswork.

  • No results found.
  • No results found.

Los Angeles, CA

Stem Cell Therapy clinics in Los Angeles

Los Angeles is one of the largest regenerative medicine markets in the country. The city combines world-class orthopedic and sports medicine specialists, research programs at Cedars-Sinai, UCLA Health, and Keck Medicine of USC, and a wellness culture that has driven steady patient demand across orthopedic, neurological, and longevity applications.

The range of providers here is wide, from hospital-affiliated research programs running FDA-authorized trials to private clinics offering autologous and allogeneic protocols under California's stem cell disclosure rules. Every clinic listed below has been reviewed against our vetting criteria, including federal provider registry checks, licensure, and treatment scope.

32 Clinics, showing page 3 of 3

MD on staff

Joint Rehab and Sports Medical Center

Los Angeles, CA

Joint Rehab and Sports Medical Center, a regenerative-medicine clinic in Los Angeles, offers cell-based therapies including stem-cell injections and bone-marrow-aspirate concentration (BMAC) alongsid…

  • PRP Therapy
  • Arthritis Treatment
  • Red Light Therapy
  • TMJ Treatment
  • Stem Cell Therapy

Joint PRP Injection Therapy

Los Angeles, CA

Joint PRP Injection Therapy, a regenerative medicine clinic in Los Angeles, specializes in orthobiologic and cell-based therapies for joint and musculoskeletal conditions. The clinic offers platelet-…

  • PRP Therapy
  • IV Therapy
  • Arthritis Treatment
  • Peptide Therapy
  • Erectile Dysfunction (ED) Treatment
15 30 50 results per page

Regulatory context

A note on California's stem cell therapy rules.

California cellular therapy providers are subject to 21 CFR Part 1271. Minimally manipulated human cells, tissues, and cellular and tissue-based products used for homologous use are regulated under Section 361 without premarket approval. Products that are more than minimally manipulated, used non-homologously, or combined with a drug or device are regulated as biologics under Section 351 and require an IND for clinical use or a BLA for marketing. Adipose-derived stromal vascular fraction, culture-expanded mesenchymal stem cells, and exosomes used for orthopedic, cosmetic, neurologic, and longevity indications are generally Section 351 products.

  • California Senate Bill 1004 (2017, Health and Safety Code Section 1644.5)
    Requires providers of non-FDA-approved stem cell therapies to post a notice to patients disclosing that the treatment has not been approved by the FDA.
  • California Proposition 71 (2004) and Proposition 14 (2020), California Institute for Regenerative Medicine
    Established and refunded CIRM to fund regenerative medicine research under strict scientific and ethical oversight.
  • California Business and Professions Code Section 651
    Prohibits false, misleading, or deceptive medical advertising, regularly cited in disciplinary actions against stem cell marketing.
  • California Business and Professions Code Section 2052 (Medical Practice Act)
    Governs physician licensure and prohibits unlicensed practice of medicine, including unauthorized administration of biologic injections.

California has been a focal point of federal enforcement. In United States v California Stem Cell Treatment Center (2022), the Ninth Circuit upheld FDA authority to regulate stromal vascular fraction as a Section 351 drug, resulting in a permanent injunction against the clinic. The FDA has issued multiple warning letters to California providers marketing stem cell and exosome therapies. The Medical Board of California has disciplined physicians for false advertising under BPC 651 and for administering unapproved biologics. The California Department of Public Health enforces tissue bank licensing. Class-action consumer suits against regenerative clinics have produced settlements.

Sources: fda.gov · leginfo.legislature.ca.gov · mbc.ca.gov · cirm.ca.gov

Stem Cell Therapy in Los Angeles, answered.

Most stem cell therapies offered in private Los Angeles clinics are not FDA-approved. The FDA has approved certain hematopoietic stem cell products for blood and immune disorders, but stem cell injections for orthopedic, neurological, or longevity use are generally investigational. California's SB 1004 requires any provider offering non-FDA-approved stem cell therapy to disclose this in writing. Hospital-affiliated research programs at Cedars-Sinai, UCLA, and Keck Medicine sometimes run FDA-authorized trials under Investigational New Drug authorizations. Ask your clinic which category their treatment falls under.

Single-joint autologous treatments typically run $4,000-$12,000 per session in the Los Angeles metro. Full-body protocols and allogeneic (donor-sourced) treatments range $8,000-$25,000 or more. Cost depends on cell source (bone marrow, adipose, or umbilical), session count, whether imaging guidance is included, and whether PRP is bundled. Insurance rarely covers stem cell therapy in LA because the FDA classifies most protocols as investigational.

Autologous stem cells are drawn from your own body, usually bone marrow or adipose tissue, and reinjected the same day. Allogeneic stem cells come from a donor source, most commonly umbilical cord blood or Wharton's jelly. LA clinics offer both. Autologous products, when minimally manipulated and used for the same tissue type, often fall under FDA Section 361 and do not require pre-market approval. Allogeneic or expanded products typically fall under Section 351 and require an active IND. Ask your clinic which category their treatment falls under.

Yes. Cedars-Sinai, UCLA Health, Keck Medicine of USC, and City of Hope regularly run FDA-authorized stem cell trials across orthopedics, neurology, cardiology, and oncology. Search clinicaltrials.gov and filter by Los Angeles to see active recruiting studies. Trial participation is generally free or low-cost compared to commercial protocols and includes structured follow-up.

Verify physician licensure through the Medical Board of California, look for NPI registry confirmation, and check the FDA warning letter database for the clinic name. Ask the clinic whether their treatment is Section 361 or Section 351, whether they operate under an IND for investigational use, and whether they comply with SB 1004 disclosure. Every clinic listed here has been checked against federal provider registries (NPI), the federal exclusion list (OIG), and the California Medical Board.

Filters

Rating

Treatments

Advanced Therapies 1
Chronic, Immune & Hormonal
Digestive & Respiratory
IV & Infusion
Pain & Musculoskeletal
Skin & Aesthetics
Mental Health & Neurology